Physician profile
Detlef Wencker
NPI 1285634881
$7,654.97
in general payments reported to CMS, 2019-2025
19 companies · $1,050 in 2025
The $1,050 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,174 · 2020: $573 · 2021: $474 · 2022: $1,334 · 2023: $257 · 2024: $1,793 · 2025: $1,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,594 · Food and Beverage: $1,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,593.79 |
| Food and Beverage | $1,506.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,278.21 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Medtronic Vascular, INC. | $1,535.66 | 2019 | |
| Cvrx, INC. | $1,465.94 | 2022-2024 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $573.24 | 2020-2024 | |
| Nuwellis, INC. | $492.03 | 2020-2022 | |
| Abiomed | $308.83 | 2021-2024 | Impella |
| E.R. Squibb & Sons, L.L.C. | $205.20 | 2025 | Camzyos |
| Daxor Corporation | $139.81 | 2022-2024 | Bva-100 |
| Medtronic, INC. | $113.34 | 2022 | |
| Merck Sharp & Dohme LLC | $99.99 | 2022-2024 | Verquvo |
| Alnylam Pharmaceuticals INC. | $98.42 | 2022-2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.75 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $72.12 | 2022-2024 | Farxiga |
| Impulse Dynamics (USA) INC. | $44.89 | 2024 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.62 | 2024-2025 | Lifevest |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $34.81 | 2022-2023 | |
| Lexicon Pharmaceuticals, INC. | $28.70 | 2024 | |
| Haemonetics Corporation | $23.84 | 2025 | Teg6s Hemostasis System |
| Bayer Healthcare Pharmaceuticals INC. | $17.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Detlef Wencker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.